

## 11 MONTHS FOR A COVID-19 VACCINE ROLL OUT FROM CONCEPTION TO APPROVAL

The first approved COVID-19 vaccine took 218 DAVS from study start to regulatory approval

In 2003,

developing an H1N1 vaccine

TOOK 5-6 MONTHS

flu vaccines was already in place

Knowledge and


infrastructure for

were brief or waived entirely based on extensive study of existing seasonal flu vaccines

Clinical trial requirements

The fastest vaccine developed until this year from scratch was the

MUMPS VACCINE TAKING JUST 4 YEARS



THE CLINICAL TRIAL PROCESS

Of all the drugs that enter clinical

trials, just 10% are approved

Updated as of Nov. 17, 2020

THE FASTEST WAY TO CURE A DISEASE

IS TO TEST AS MANY OPTIONS AS POSSIBLE

**DRUG DEVELOPMENT PROGRAMS** 

IN PLANNING STAGES

**COVID 19 TREATMENTS** 

**CURRENTLY AUTHORIZED** 

# PROGRAM (CTAP) DASHBOARD 560+

CORONAVIRUS TREATMENT ACCELERATION

TRIALS REVIEWED

FOR EMERGENCY USE TREATMENTS CURRENTLY APPROVED BY FDA

FOR USE IN COVID 19

STAGE OF COVID-19 TRIALS IN THE U.S.

EARLY STAGE (trials testing safety and dosing) Currently there are 19 COVID-19

**CLINICAL TRIAL PHASES** 

— 20-100 healthy volunteers receive — increasing doses until side effects appear

Determines how the drug is metabolized and potential side effects

LATE STAGE

(trials testing safety and dosing)

### next phase

**VACCINES IN** 

PHASE I TRIALS

Approximately 70%

of drugs move to the

PRE- CLINICAL TRIALS

PHASE II TRIALS

next phase

**SAFETY & DOSAGE** 

**EFFICACY & SIDE EFFECTS** Approximately 33% of drugs move to the

PHASE III TRIALS

Approximately 25-30%

of drugs move to the

**EFFICACY AND MONITORING** 

**OF ADVERSE REACTIONS** 

next phase

100-500 affected patients are given the drug to observe its effects



Determines drug safety, efficacy, dosing and patient outcomes

= 300 volunteers

Researchers may begin to

explore possible uses of the

drug for other indications

When repurposing an already tested

and approved drug, researchers can

often bypass phase 1 trials

20%

= 20 volunteers

= 100 volunteers

Length of study is 1 to 4 years After phase 3 trials, the FDA determines if the drug can be approved for market

Compares the new drug to standard of care at multiple dosing levels

Data is use to develop labeling information and treatment regimens

### PHASE IV TRIALS

electronic health records

CHALLENGES For Clinical Trials

**Continue to monitor long** 

term safety and efficacy

using real world data

Such as anonymized

insurance claims and

The FDA has promised to expedite development

timelines for prevention and treatment options for COVID-19

Including emergency authorizations for existing drugs used to treat other diseases

### **patients** are needed for In order to find the 2 million needed, 46 million patients are recruited clinical trials every year — That's more than the population of Spain

5%

LACK OF DIVERSITY Both drugs and diseases (including COVID-19) may affect diverse populations differently

LOW ENROLLMENT

More than two million

make up less than 5% of trial participants, but

20% of the U.S. population 5%

**African Americans** 

Just 5% of the patients recruited actually enroll

Interested in joining a trial? clinicaltrials.gov

Similar disparities exist among Asian and Native American populations

**WE ALL BENEFIT** 

or contact a patient advocacy group and

start a conversation with your doctor

Presented by:

Now more than ever

Socioeconomic barriers and a history of victimization in medical experiments may contribute to minorities unwillingness to participate in clinical trials

Sources: remapcap.org youtu.be/tpBROVT3KY8?t=80 ncbi.nlm.nih.gov/pmc/articles/PMC6226120 wired.com/story/moderna-covid-19-vaccine-trials

healthline.com/health/herd-immunity#how-it-works

scientificamerican.com/article/how-the-covid-19-pandemic-could-end1 raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker FROM CLINICAL TRIALS vox.com/2020/4/13/21215133/coronavirus-testing-covid-19-tests-screening

S MEDIDATA

smithsonianmag.com/science-nature/can-you-become-immune-sars-cov-2-180974532 vox.com/2020/4/14/21218074/coronavirus-plans-social-distancing-end-reopen-economy fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations medidata.com/wp-content/uploads/2020/05/COVID19-Response4.0\_Clinical-Trials\_2020504\_v3.pdf biospace.com/article/the-importance-of-diversity-in-clinical-trials-because-right-now-it-s-lackingnews.bloomberglaw.com/coronavirus/senators-say-minorities-women-must-be-part-of-covid-19-tests fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap#snapshot

https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap#snapshot

fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment

https://www.clinicaltrials.gov/ct2/show/NCT04368728 medicinenet.com/script/main/art.asp?articlekey=9877 who.int/csr/disease/swineflu/notes/h1n1\_vaccine\_20090806/en monmouth.edu/polling-institute/reports/monmouthpoll\_us\_051120 https://www.fda.gov/patients/drug-development-process/step-3-clinical-research the-scientist.com/features/repurposing-existing-drugs-for-new-indications-32285

businesswire.com/news/home/20200414005276/en/Moderna-Highlights-Opportunity-mRNA-Vaccines-Vaccines-Day

NOWSOURCING